AstraZeneca PLC (OTCMKTS:AZNCF) Sees Significant Increase in Short Interest

AstraZeneca PLC (OTCMKTS:AZNCF) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 192,900 shares, an increase of 31.0% from the November 15th total of 147,200 shares. Based on an average trading volume of 4,800 shares, the short-interest ratio is currently 40.2 days.

Institutional Trading of AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Eagle Bay Advisors LLC bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,001 shares of the company’s stock, valued at approximately $156,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.

AstraZeneca Stock Down 0.5 %

AZNCF stock traded down $0.68 during midday trading on Friday, reaching $131.74. The company had a trading volume of 3,095 shares, compared to its average volume of 2,669. AstraZeneca has a 1-year low of $118.16 and a 1-year high of $175.00. The stock has a 50 day moving average price of $139.09 and a 200-day moving average price of $152.32.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.